Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse
17.3.2025 23:00:00 CET | Business Wire | Press release
Queensland’s major airport pioneers data consolidation in the cloud to drive operational efficiency
Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/
Brisbane Airport
Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis.
Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand.
“Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to consolidate and accelerate digitization, leading to improved decision-making and operational performance.
"Our data will be a crucial asset in driving efficiency and elevating the traveler experience at Brisbane Airport."
Ryan Both, Brisbane Airport Executive General Manager Aviation said: “Accessing Cirium’s schedules data through Cirium Sky Warehouse enables advanced automation, marking a critical step in Brisbane Airport’s digital transformation project.”
“The schedules data plays a critical role in creating and executing more accurate flight schedules, planning for future events and fluctuations in air traffic, gaining more comprehensive insights, and making decisions for business growth. This will lead to numerous improvements around efficiency, sustainability and passenger experience.”
“Embracing a cloud-based data integration approach also means we will significantly reduce the time spent internally on data and ultimately drive cost efficiencies.”
Brisbane Airport is currently undergoing a transformation program known as Future BNE, which includes 150 projects over a 10-year period, focusing on upgrades to the airport’s domestic and international terminals, as well as planning for a third terminal, ahead of the city hosting the 2032 Olympics.
This first phase modernization will support an improved experience for the almost 25 million passengers currently passing through its terminals and the additional 10 million expected over the coming decade.
The Cirium Sky Warehouse delivers the highest quality aviation data and analytics in one accessible data cloud, aligning seamlessly with Brisbane Airport’s digital transformation objectives. While the airport will initially leverage schedules data, a wealth of other data can be accessed and integrated from Cirium Sky Warehouse including flight, traffic, fleet, fares, weather, and CO2 emissions.
By leveraging the power of Cirium’s data cloud, Brisbane Airport joins global major airlines, fuel supply companies, aviation financiers, and more in enhancing its planning, operational efficiency and growth opportunities.
Notes to editors
To find out more about the Cirium Sky Warehouse, click here.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth. Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. For further information please follow Cirium on LinkedIn or visit cirium.com.
About Brisbane Airport
BNE is the third-largest airport in Australia by passenger numbers, with 24 million passengers travelling through the airport annually. BNE contributes $4.7 billion GDP annually, with 1 in 70 Queensland jobs enabled by BNE and benefits provided range of key industries such as tourism, resources and international education. BNE is the largest airport in Australia by land size, covering 2,700 hectares of land used for aviation, property development and consumer businesses, which employ over 20,000 people. In 2025 it celebrates 100 years of operation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317052819/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom